Eagle Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Eagle Pharmaceuticals is Mike Graves, benoemd in Jan2023, heeft een ambtstermijn van 11.17 jaar. bezit rechtstreeks 0.08% van de aandelen van het bedrijf, ter waarde $ 5.18K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 8.2 jaar.

Belangrijke informatie

Mike Graves

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2yrs
Eigendom CEO	0.08%
Management gemiddelde ambtstermijn	2.5yrs
Gemiddelde ambtstermijn bestuur	8.2yrs

Recente managementupdates

Recent updates

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Oct 27

Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia

Oct 12

Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose

Sep 27

Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court

Aug 18

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Aug 15

Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M

Aug 09

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Jul 06

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Apr 29

CEO

Mike Graves (61 yo)

2yrs

Tenure

US$391,026

Compensatie

Mr. Michael Graves, also known as Mike, is Interim Principal Executive Officer of Eagle Pharmaceuticals, Inc. from 2023. He had been the Independent Chairman of Eagle Pharmaceuticals Inc. since June 2016 u...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Graves	Interim Principal Executive Officer & Executive Chairman of the Board	2yrs	US$391.03k	0.080% $ 5.2k
Christopher Krawtschuk	CFO and Principal Financial & Accounting Officer	less than a year	geen gegevens	geen gegevens
Daniel O'Connor	Executive VP	7.7yrs	geen gegevens	geen gegevens
Valentin Curt	Senior Vice President of Clinical Drug Development	4.2yrs	geen gegevens	geen gegevens
Gaozhong Zhu	Senior Vice President of Pharmaceutical Development	4.2yrs	geen gegevens	geen gegevens
Debra Hussain	Senior VP & Head of Commercial	2.5yrs	geen gegevens	geen gegevens
Reed McClung	Executive Vice President of Oncology Business Development	2yrs	geen gegevens	geen gegevens

2.5yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van EGRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Graves	Interim Principal Executive Officer & Executive Chairman of the Board	11.2yrs	US$391.03k	0.080% $ 5.2k
Steven Ratoff	Director	17.8yrs	US$331.03k	geen gegevens
Richard Edlin	Independent Director	7.8yrs	US$312.28k	geen gegevens
Robert Glenning	Independent Director	8.5yrs	US$324.78k	geen gegevens
Jennifer Simpson	Lead Independent Director	5.4yrs	US$308.53k	geen gegevens
Luciana Borio	Independent Director	3.8yrs	US$308.53k	geen gegevens

8.2yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van EGRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.2 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/01/02 15:29
Aandelenkoers aan het einde van de dag	2025/01/02 00:00
Inkomsten	2023/06/30
Jaarlijkse inkomsten	2022/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Eagle Pharmaceuticals, Inc. wordt gevolgd door 6 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Louise Chen	Cantor Fitzgerald & Co.
Irina Rivkind Koffler	Mizuho Securities USA LLC
David Amsellem	Piper Sandler Companies

Eagle Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Eagle Pharmaceuticals, Inc. Announces Chief Financial Officer Changes

Eagle Pharmaceuticals, Inc. Announces Board and Committee Changes

Eagle Pharmaceuticals, Inc. Announces Resignation of Scott Tarriff as Chief Executive Officer

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Founder recently sold US$931k worth of stock

Recent updates

Eagle Pharmaceuticals to File Form 25 with the SEC to Complete the Process of Delisting of its Common Stock from the Nasdaq Global Market

Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing

Eagle Pharmaceuticals, Inc. Announces Chief Financial Officer Changes

Hearings Panel of The Nasdaq Stock Market LLC Determines to Delist Eagle Pharmaceuticals' Common Stock from Nasdaq

Eagle Pharmaceuticals, Inc.(OTCPK:EGRX) dropped from NASDAQ Composite Index

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing

Eagle Pharmaceuticals, Inc. and Curia Global, Inc. Enters into Settlement Agreement in AAA Case No. 01-23-0000-2937

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 3000 Index

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K

Eagle Pharmaceuticals, Inc. announced delayed annual 10-K filing

Eagle Pharmaceuticals, Inc. Announces Board and Committee Changes

New minor risk - Financial data availability

Investor sentiment improves as stock rises 19%

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Eagle Pharmaceuticals, Inc

Eagle Pharmaceuticals, Inc. Announces Resignation of Scott Tarriff as Chief Executive Officer

Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing

Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Investor sentiment deteriorates as stock falls 32%

Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Founder notifies of intention to sell stock

Centers for Medicare & Medicaid Services Establishes Unique, Product-Specific Billing Code and Grants Transitional Pass-Through Payment Status for Barhemsys (Amisulpride) Injection by Eagle Pharmaceuticals, Inc

Founder notifies of intention to sell stock

Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?

Investor sentiment deteriorates as stock falls 18%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Eagle Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Eagle Pharmaceuticals, Inc. Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, A Novel First-In-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia

Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Growth-Defensive Index

Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly

New major risk - Revenue and earnings growth

Eagle Pharmaceuticals, Inc. Receives FDA Qualified Infectious Disease Product (Qidp) and Fast-Track Designation for Cal02, Providing Five-Year Exclusivity Extension

Founder recently sold US$931k worth of stock

Founder notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates fall by 20%

Eagle Pharmaceuticals, Inc. Receives FDA Approval for Additional Indication for PEMFEXY in Combination with Pembrolizumab and Platinum Chemotherapy

Consensus forecasts updated

Insufficient new directors

Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Eagle Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle Pharmaceuticals, Inc Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02

Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia

Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.

Independent Director recently sold US$211k worth of stock

Insufficient new directors

U.S. Court of Appeals for the Federal Circuit Affirms the U.S. District Court for the District of Delaware’s Decision That Eagle Pharmaceuticals, Inc.'s Vasopressin Product Does Not Infringe on Any of the Patents Asserted by Par Pharmaceutical, Inc

Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court

Consensus revenue estimates fall by 21%

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Price target decreased to US$43.00

Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M

Eagle Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Michael Moran Separates as Executive Vice President, Chief Commercial Officer of Eagle Pharmaceuticals, Inc

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle Pharmaceuticals, Inc., Annual General Meeting, Jul 28, 2022

Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) completed the acquisition of Acacia Pharma Group plc (ENXTBR:ACPH) from a group of shareholders.

Eagle Pharmaceuticals, Inc. Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, A Beta-1 Adrenergic Blocker

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Now 20% undervalued